KEGG   DRUG: Dolutegravir, abacavir and lamivudineHelp
Entry
D10600            Mixture   Drug                                   

Name
Dolutegravir, abacavir and lamivudine;
Triumeq (TN)
Product
Component
(Dolutegravir sodium [DR:D10113] | Dolutegravir [DR:D10066]), Abacavir sulfate [DR:D00891], Lamivudine [DR:D00353]
Remark
Therapeutic category: 6250
ATC code: J05AR13
Product: D10600<JP/US>
Efficacy
Antiviral
  Disease
HIV-1 infection [DS:H01563]
Comment
Dolutegravir is metabolized by UGT1A1 with some contribution from CYP3A4.
Dolutegravir is an inhibitor of OCT2 and MATE1.
Avacavir is a substrate of alcohol dehydrogenase/aldehyde dehydrogenase as well as UGT2B7.
Lamivudine is a substrate of OCT2, MATE1 and MATE2-K.
Metabolism
Enzyme: UGT1A1 [HSA:54658], UGT2B7 [HSA:7364]; CYP3A4 [HSA:1576]
Transporter: SLC22A2 [HSA:6582], SLC47A1 [HSA:55244], SLC47A2 [HSA:146802]
Interaction
Transporter inhibition: SLC22A2 [HSA:6582], SLC47A1 [HSA:55244]
Drug interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 J ANTIINFECTIVES FOR SYSTEMIC USE
  J05 ANTIVIRALS FOR SYSTEMIC USE
   J05A DIRECT ACTING ANTIVIRALS
    J05AR Antivirals for treatment of HIV infections, combinations
     J05AR13 Lamivudine, abacavir and dolutegravir
      D10600  Dolutegravir, abacavir and lamivudine <JP/US>
USP drug classification [BR:br08302]
 Antivirals
  Anti-HIV Agents, Other
   Abacavir/ Dolutegravir/ Lamivudine
    D10600  Dolutegravir, abacavir and lamivudine
Therapeutic category of drugs in Japan [BR:br08301]
 6  Agents against pathologic organisms and parasites
  62  Chemotherapeutics
   625  Antivirals
    6250  Antivirals
     D10600  Dolutegravir, abacavir and lamivudine
Antiinfectives [br08350.html]
 Antivirals
  D10600
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D10600
BRITE hierarchy
Other DBs
PubChem: 254741562
LinkDB All DBs

» Japanese version   » Back

DBGET integrated database retrieval system